aTyr Pharma (NASDAQ:ATYR) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of aTyr Pharma (NASDAQ:ATYR) from a sell rating to a hold rating in a research note published on Sunday.

Separately, Jefferies Financial Group reiterated a “buy” rating on shares of aTyr Pharma in a research note on Friday, March 6th. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, aTyr Pharma has an average rating of “Hold” and an average price target of $25.67.

aTyr Pharma Stock Performance

NASDAQ ATYR opened at $0.50 on Friday. The company has a fifty day simple moving average of $0.81 and a 200 day simple moving average of $0.81. The company has a market cap of $49.42 million, a P/E ratio of -0.69 and a beta of 0.66. aTyr Pharma has a 1 year low of $0.40 and a 1 year high of $7.29.

aTyr Pharma (NASDAQ:ATYR) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. Equities research analysts forecast that aTyr Pharma will post -0.69 EPS for the current fiscal year.

Hedge Funds Weigh In On aTyr Pharma

Several large investors have recently added to or reduced their stakes in the company. UBS Group AG raised its stake in shares of aTyr Pharma by 158.1% in the 3rd quarter. UBS Group AG now owns 4,505,955 shares of the company’s stock valued at $3,249,000 after buying an additional 2,760,238 shares in the last quarter. GSA Capital Partners LLP raised its stake in shares of aTyr Pharma by 272.2% in the 4th quarter. GSA Capital Partners LLP now owns 2,630,638 shares of the company’s stock valued at $2,060,000 after buying an additional 1,923,907 shares in the last quarter. Millennium Management LLC raised its stake in shares of aTyr Pharma by 334.5% in the 1st quarter. Millennium Management LLC now owns 1,599,041 shares of the company’s stock valued at $4,829,000 after buying an additional 1,231,052 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of aTyr Pharma by 21.0% in the 3rd quarter. Vanguard Group Inc. now owns 5,630,935 shares of the company’s stock valued at $4,060,000 after buying an additional 975,887 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new position in shares of aTyr Pharma in the 4th quarter valued at $603,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.